• 1
    Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316: 889897.
  • 2
    Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. N Engl J Med. 1998; 338: 12721278.
  • 3
    Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000; 343: 750758.
  • 4
    Battegay EJ. Angiogenesis: mechanistic insights, neovascular diseases, and therapuetic prospects. J Mol Med. 1995; 73: 333346.
  • 5
    Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995; 1: 2731.
  • 6
    Nanus DM, Schmitz-Drager BJ, Motzer RJ, et al. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst. 1993; 85: 15971579.
  • 7
    D'Amato RJ, Loughnan MS, Flynn E, Folkman Jl. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994; 91: 40824085.
  • 8
    Kenyon BM, Browne F, D'Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 1997; 64: 971978.
  • 9
    Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med. 1991; 173: 699703.
  • 10
    Rowland TL, McHugh SM, Deighton J, Dearman RJ, Ewan PW, Kimber I. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells. Immunopharmacology. 1998; 40: 1120.
  • 11
    Shannon EJ, Sandoval F. Thalidomide increases the sythesis of IL-2 in cultures of human mononuclear cells stimulated with concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology. 1995; 31: 109116.
  • 12
    Sampio EP, Kaplan G, Miranda A, et al. The influence of thalidomide on the clinical and immunologic manifestations of erythema nodosum leprosum. J Infect Dis. 1993; 168: 408414.
  • 13
    Singhal S, Metha J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341: 15651571.
  • 14
    Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med. 2000; 108: 487495.
  • 15
    Little RF, Wyvill KM, Pluda JM, et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000; 18: 25932602.
  • 16
    Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol. 2000; 18: 708715.
  • 17
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 18
    Cox DR. Regression models and life tables (with discussion). J R Stat Soc [B]. 1972; 34: 187220.
  • 19
    Therneau TM, Grambsch PM. Modeling survival data. New York: Springer, 2000.
  • 20
    Becker RA, Chambers JM, Wilks AR. The new S language. Pacific Grove, CA: Wadsworth, 1988.
  • 21
    Therneau TM. A package for survival analysis in S. Mayo Clinic Foundation, 1994, Rochester, Minnesota.
  • 22
    Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999; 17: 25302540.
  • 23
    Figg WD, Raje S, Bauer KS, et al. Pharmacokinetics of thalidomide in an elderly prostate cancer population. J Pharm Sci. 1999; 88: 121125.
  • 24
    Eisen T, Boshoff C, Mak I, et al. Continuous low-dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian, and breast cancer. Br J Cancer. 2000; 82: 812817.
  • 25
    Li Z, Amato R, Papandreou CN, et al. Phase II study of thalidomide for patients with metastatic renal cell carcinoma progressing after interleukin-2 (IL-2)-based therapy [Abstract]. Proc Am Soc Clin Oncol. 2001; 20: 180a.
  • 26
    Escudier B, Lassau N, Couanet D, et al. A phase II trial of thalidomide in renal cell carcinoma [Abstract]. Proc Am Soc Clin Oncol. 2001; 20: 180a.
  • 27
    Novik Y, Dutcher JP, Larkin M, Wiernik PH. Phase II study of thalidomide (T) in advanced refractory metastatic renal cell carcinoma (MRCC): a single institution experience [Abstract]. Proc Am Soc Clin Oncol. 2001; 20: 265a.
  • 28
    Motzer RJ, Berg W, Ginsberg M, et al. Phase II trial of thalidomide in patients with advanced renal cell carcinoma. J Clin Oncol. 2002; 20: 302306.
  • 29
    Aulitzky W, Gastl G, Aulitzky WE, et al. Successful treatment of metastatic renal cell carcinoma with a biologically active dose of IFN-(gamma). J Clin Oncol. 1989; 7: 18751884.
  • 30
    Ellerhorst JA, Kilbourn RG, Amato RJ, Zukinski AA, Jones E, Logothetis CJ. Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma. J Urol. 1994; 152: 841845.
  • 31
    Quesada JR, Rios A, Swanson D, Trown P, Gutterman JU. Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol. 1985; 3: 15221528.
  • 32
    Figlin RA, deKernion JB, Mukamel E, Palleroni AV, Itri LM, Sarna GP. Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol. 1988; 6: 16041610.
  • 33
    Gleave ME, Elhilali M, Fradet Y, et al. Interferon Gamma-1b compared with placebo in metastatic renal-cell carcinoma. N Engl J Med. 1998; 338: 12651271.